Omics analysis of HIV during synthetic opioid exposure
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
20192021Known Financial Commitments (USD)
$150,215Funder
National Institutes of Health (NIH)Principal Investigator
PendingResearch Location
United States of AmericaLead Research Institution
UNIVERSITY OF CINCINNATIResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Prognostic factors for disease severity
Special Interest Tags
Data Management and Data SharingInnovation
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Adults (18 and older)
Vulnerable Population
Drug users
Occupations of Interest
Unspecified
Abstract
Abstract In December 2019, an outbreak of pneumonia of unknown cause occurred in Wuhan, China, and thecausative agent was identified as a novel coronavirus named severe acute respiratory syndrome coronavirus2 (SARS-CoV-2). Additionally, the US is in the midst of a major opioid epidemic largely attributed to synthetic opioids such as fentanyl, and the SARS-CoV-2 pandemic is occurring in parts of the world where recent increases in HIV due to the opioid crisis have been reported. With the SARS-CoV-2 pandemic, there are major concerns about worsening of the opioid crisis. People suffering from addiction are particularly vulnerable to increased infection with SARS-CoV-2 and more advanced disease severity. Many opioids are also associated with immune suppression and enhanced viral pathogenesis. Thus, foundational research on virus-virus and virus-opioid interactions is essential for understanding the impact of SARS-CoV-2 on other co-morbid conditions and for developing robust therapeutic options for limiting viral infection and pathogenesis in high-risk populations.